Author

G. Bismuth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Trautmann· 2 shared E. Donnadieu· 2 shared L. Vimeux· 2 shared N. Bercovici· 2 shared V. Feuillet· 2 shared A. Bouaboud· 1 shared C. Daher· 1 shared E. Peranzoni· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Trautmann

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

LPS induces GFAT2 expression to promote O-GlcNAcylation and attenuate inflammation in macrophages

H. Al-Mukh, L. Baudoin, A. Bouaboud, J.-L. Sanchez-Salgado, N. Maraqa, M. Khair, P. Pagesy, G. Bismuth, F. Niedergang, T. Issad

This study shows LPS increases GFAT2 expression in macrophages, enhancing O-GlcNAcylation and reducing inflammation.

bioRxiv · Mar 22, 2020Biochemistry

TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors

M. V. V. Guerin, F. Regnier, V. Feuillet, L. Vimeux, J. M. Weiss, G. Bismuth, G. Altan-Bonnet, T. Guilbert, M. Thoreau, V. Finisguerra, E. Donnadieu, A. Trautmann, N. Bercovici

This study shows that TGFβ inhibits IFNα/β production and tumor rejection in spontaneous mammary tumors, and blocking TGFβ enhances DMXAA-induced tumor regression.

bioRxiv · Jul 9, 2019Cancer Biology

Blockade of β-adrenergic receptor signaling improves cancer vaccine efficacy through its effect on naive CD8+ T-cell priming

C. Daher, L. Vimeux, R. Stoeva, E. Peranzoni, G. Bismuth, E. Donnadieu, N. Bercovici, A. Trautmann, V. Feuillet

This study shows that blocking β-adrenergic receptor signaling enhances cancer vaccine efficacy by improving naive CD8+ T-cell priming, without affecting tumor-infiltrating CD8+ T-cell reactivity.

bioRxiv · Dec 16, 2018 · PreprintImmunology